Generex Biotechnology has reached an agreement with Amarantus BioSciences regarding Generex’s RapidMist buccal aerosol delivery system. The RapidMist device is a modified metered dose inhaler that delivers the aerosol to the lining of the mouth instead of to the lungs. Amarantus, which is paying Generex $10 million for use of the technology, will use it to deliver MANF proteins.
The RapidMist device was developed by Generex for its Oral-lyn buccal insulin product, and this is the first time that the company has out-licensed the technology. According to the company’s President and CEO Mark Fletcher, they intend to continue to look for opportunities to use the device for other products and “look forward to the broader validation of our platform.”
Read the Generex press release.
